U.S. markets closed

uniQure N.V. (QURE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
37.00-0.47 (-1.25%)
At close: 4:00PM EST

35.00 -2.00 (-5.41%)
After hours: 7:53PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close37.47
Bid35.53 x 800
Ask36.84 x 800
Day's Range35.77 - 37.43
52 Week Range33.59 - 71.45
Avg. Volume548,321
Market Cap1.646B
Beta (5Y Monthly)1.23
PE Ratio (TTM)N/A
EPS (TTM)-3.75
Earnings DateOct 27, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est68.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Is uniQure (NASDAQ:QURE) Using Debt Sensibly?
    Simply Wall St.

    Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

  • The Bullish Piece Of News That Caused This Gene Therapy Stock To Pop
    Investor's Business Daily

    The Bullish Piece Of News That Caused This Gene Therapy Stock To Pop

    Uniqure said Monday an independent panel recommended it continue enrolling patients in a study of its Huntington's disease gene therapy. In response, QURE stock popped on the news.

  • MarketWatch

    UniQure's stock rallies 7% on positive safety data for Huntington's disease treatment

    Shares of UniQure gained 7.2% in trading on Monday after the company said an independent data safety monitoring board said there were no safety concerns in a Phase 2/3 clinical trial for its experimental Huntington's disease treatment. The board has reviewed six months of safety data for the first two patients enrolled in the randomized, double-blind study. UniQure said it expects to enroll six more patients who have been diagnosed with the rare neurodegenerative disease by mid-2021. The investigational gene therapy is called AMT-130. "While early, we remain bullish about uniQure's [Huntington's disease] gene therapy and continue to believe the program is nearly all upside from current levels," Raymond James analyst Danielle Brill wrote in a note to investors. Uniqure's stock is down 35.9% for the past year, while the broader S&P 500 has gained 16.5%.